NCT07120282 2026-03-09Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLCCancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2 Recruiting108 enrolled